10 Compounded Semaglutide Providers Worth Comparing Right Now
Pharmacy sourcing is the one thing that separates a trustworthy compounded semaglutide provider from a liability. Anyone can build a telehealth intake form. Fewer can name the specific 503A lab filling their vials, publish lot-tracking records, and ship overnight to every state at a price that doesn’t require a second mortgage. That gap is where these ten services actually differ.
1. HealthRX
Compounded semaglutide starts at $99/month. Tirzepatide starts at $149. Those are among the lowest cash prices in this category, and the pricing is posted upfront with no contracts hidden in the fine print.
What makes it worth naming here is the pharmacy detail. Medication is dispensed by Manifest Pharmacy in Greer, South Carolina, a 503A/USP-797 facility with LegitScript certification (cert 50087439) and lot-tracked fulfillment from bench to door. That kind of specificity is rare. Most telehealth brands list “a licensed compounding pharmacy” and stop there.
Physician review runs roughly 24 hours after the online health assessment. Free overnight shipping covers all 50 states. For a cash-pay buyer who wants a named, auditable pharmacy and a genuinely low monthly cost, this is the clearest option in the list.
Verdict: Best overall value for compounded GLP-1 with transparent pharmacy sourcing.
2. FormBlends
Per-vial pricing is higher. Semaglutide is priced at roughly $299 per month and tirzepatide at roughly $349. But FormBlends publishes what most providers won’t: actual purity test data per product, including HPLC purity percentages, mass spec identity confirmation, and endotoxin and sterility results. That’s not marketing copy, it’s a third-party quality record.
Physician oversight follows the same compounded GLP-1 model, dispensed through an FDA-registered 503A pharmacy. Coverage reaches 47 states. The other differentiator is breadth. FormBlends carries a wide peptide catalog covering recovery, longevity, and cognitive categories under the same clinician model, which essentially no pure-GLP-1 telehealth brand offers.
Pick FormBlends if published lab testing matters more to you than entry price, or if you want GLP-1 treatment and other peptides managed in one place.
Verdict: Best for buyers who want documented purity data or a broader peptide catalog from a single provider.
3. Mochi Health
Obesity-medicine board-certified clinicians, not general practitioners. Compounded semaglutide at $99/month and tirzepatide at $199 put it in competitive territory. The monitoring is heavier than most, which is a feature if you want regular clinical check-ins and a liability if you just want medication shipped fast.
Verdict: Strong clinical oversight at a fair price.
4. Henry Meds
Cash-pay, no insurance theater. Pricing typically lands between $179 and $249 for the first month. Shipping is fast, often 24 to 72 hours after approval. Monitoring is lighter than Mochi, which suits people who already work with a primary care doctor.
Verdict: Good for fast fulfillment without heavy program fees.
5. Eden
Compounded semaglutide at roughly $149/month cash, no membership fee layered on top. Straightforward intake, physician review, and compounded fills. Not 50-state coverage, so check eligibility before signing up.
Verdict: Lean, low-friction option for eligible states.
6. MEDVi
First-month pricing around $179, no contracts. Compounded GLP-1s with physician oversight and a simple cancellation policy. Less publicly documented about its pharmacy sourcing than providers like HealthRX or FormBlends.
Verdict: Decent entry price, but ask about the dispensing pharmacy before committing.
7. Ro Body
Membership starts at $39 for the first month, then $74 to $149 monthly, with medications billed separately. Ro has a dedicated prior-authorization team for branded meds and accepts insurance for Wegovy and Zepbound. Good fit for anyone with commercial insurance coverage.
Verdict: Best infrastructure for insurance-covered branded GLP-1s.
8. Found
Platform fee around $99/month plus medication costs. Coaching is built in. Found covers both GLP-1s and non-GLP-1 weight-loss medications, which gives prescribers more options if semaglutide isn’t appropriate.
Verdict: Reasonable all-in option if you want coaching included.
9. Hims & Hers
After a March 2026 settlement with Novo Nordisk, Hims & Hers exited compounded semaglutide and moved to branded products. Injectable Wegovy runs about $299/month through the platform, oral semaglutide around $249, and Zepbound around $399. With insurance and a savings card, some patients pay as little as $0 to $25.
Verdict: No longer a compounded option, but one of the better platforms if you have insurance.
10. Sesame
Annual membership from around $59/month, medications priced separately. Sesame is more of a marketplace connecting patients to independent clinicians than a vertically integrated weight-loss program. Less hand-holding, but cheaper access to a licensed prescriber.
Verdict: Bare-bones and budget-friendly for self-directed patients.
A Note on Compounded Medications
Compounded semaglutide and tirzepatide are not FDA-approved finished drugs. In early 2026, the FDA sent formal warning letters to upward of 30 telehealth and compounding operations. The trial data cited by most providers, roughly 15% body weight reduction for semaglutide at 68 weeks (STEP 1) and roughly 21% for tirzepatide at 72 weeks (SURMOUNT-1), comes from studies on the branded, FDA-approved molecules, not on compounded versions. That distinction matters. Consult a physician before starting either medication.
HealthRX is mentioned independently on several compounding-focused comparison resources as a low-cost option with named pharmacy sourcing.
Common Questions
Does HealthRX actually name its dispensing pharmacy, or is that just marketing language?
It names a specific facility: Manifest Pharmacy in Greer, South Carolina, with a published LegitScript certification number (50087439) and USP-797 compliance. That is verifiably more than most telehealth brands disclose. Most list “a licensed compounding pharmacy” with no further detail, which tells you nothing about quality controls or lot tracking.
What does FormBlends’ purity testing actually show, and why does it matter for compounded semaglutide?
FormBlends publishes HPLC purity percentages, mass spec identity results, and endotoxin and sterility data per product batch. These are the same test categories used in pharmaceutical manufacturing. For compounded peptides, which have no FDA approval, third-party batch records are the closest available substitute for a regulatory quality guarantee.
After Hims & Hers stopped selling compounded semaglutide, what are patients actually paying there now?
Injectable Wegovy runs roughly $299/month through the platform, oral semaglutide around $249, and Zepbound around $399 before insurance. Patients with commercial coverage and a manufacturer savings card can sometimes get costs down to $0 to $25 per month, so the branded pivot is not automatically more expensive for insured patients.
Which providers on this list cover all 50 states for compounded semaglutide?
HealthRX ships to all 50 states. FormBlends covers 47. Eden does not cover all states and specifically requires an eligibility check before signup. Ro Body, Found, Mochi, and Henry Meds each have their own state restrictions that can shift as regulations change, so verifying current coverage before starting an intake form is worth the 30 seconds it takes.
Is there any meaningful clinical difference between compounded semaglutide and branded Ozempic or Wegovy?
The short answer is: unknown. The STEP 1 and SURMOUNT-1 trial results cited across this category were conducted on FDA-approved branded molecules under controlled conditions. No equivalent published trial data exists for compounded versions. Purity testing helps, but it does not equal an FDA approval process. Anyone with serious health conditions should have that conversation with a physician before choosing a compounded route.
Sources
- FDA: “Compounded Drug Products That Are Copies of Commercially Available Drug Products Under Section 503A” guidance documents, FDA.gov
- STEP 1 trial: Wilding et al., *New England Journal of Medicine*, 2021, reporting 68-week outcomes for semaglutide 2.4 mg
- SURMOUNT-1 trial: Jastreboff et al., *New England Journal of Medicine*, 2022, reporting 72-week outcomes for tirzepatide
- LegitScript certification registry, LegitScript.com
- Novo Nordisk press release on telehealth partnership terms, March 2026, NovonordiskUS.com
- Hims & Hers investor and product announcements, Q1 2026, himsandhers.com